Daniel Lucey - September 9, 2020

Daniel Lucey, MD, MPH, Senior Scholar, O’Neill Institute for National and Global Health Law, Georgetown University Law Center, Adjunct Professor of Medicine-Infectious Diseases, Georgetown University Medical Center, "COVID Vaccine Trials on 6 Continents"

There are currently 34 COVID-19 vaccines in clinical trials across the six continents, and nine of them have reached Phase III. In this talk, Dr. Lucey gives short summaries of each Phase III trial. The University of Oxford/AstraZeneca (UK-Sweden) trial has tens of thousands of volunteers in the UK, India, Brazil, South Africa and the US, and is continuing after a temporary pause on September 8. Moderna (US) in partnership with National Institute of Allergies and Infectious Diseases (NIAID), and Pfizer (US) in partnership with BioNTech (Germany) and FosunPharma (China) are developing RNA based vaccine platforms. Three trials are using adenovirus (non replicating viral vector) platforms: the CanSino Biological Inc./Beijing Institute of Biotechnology trial is occurring entirely in Pakistan, the Gamaleya Research Institute trial has enrolled 40,000 volunteers in Russia, and the Johnson & Johnson (US) trial has entered Phase III but has not yet begun enrollment. Finally, the Sinovac (China) trials as well as two distinct Sinopharm (China) trials are based on inactivated vaccine candidates and are happening in Brazil, Indonesia and the United Arab Emirates.

A non-technical summary of the vaccine trials across all phases can be found on the NYT website: https://www.nytimes.com/interactive/2...